In a landmark development that could transform the affordability of critical medications for millions of Americans, the Trump administration has finalized a historic agreement with pharmaceutical powerhouses Eli Lilly and Novo Nordisk to significantly reduce the prices of GLP-1 drugs by 2026. These
In the relentless fight against malaria, particularly the deadly Plasmodium falciparum strain, late treatment failure stands as a formidable barrier to global health progress, characterized by the reappearance of malaria parasites in the bloodstream after an initially successful drug response. This
The pharmaceutical industry stands as a pillar of modern healthcare, tirelessly working to develop life-saving medications through rigorous research and development efforts that often span years and cost billions. Yet, the very system designed to protect and incentivize this innovation—the patent
In a chilling development for healthcare systems across the United States, a dramatic increase in multidrug-resistant bacteria known as carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) has emerged as a formidable challenge in hospitals, often dubbed a "superbug" due to its
In the heart of New Orleans, a small HIV outreach ministry faces an impossible choice: cut essential supplies like condoms or lay off staff who keep the operation running, reflecting a broader crisis rippling across the United States in 2025. Behind closed doors, Russell Vought, director of the
In the fast-paced realm of pharmaceutical advancements, few stories capture attention like the regulatory journey of Sanofi’s tolebrutinib, a potential game-changer for non-relapsing secondary progressive multiple sclerosis (nrSPMS). This Bruton’s tyrosine kinase (BTK) inhibitor, aimed at slowing
